AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
-
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
-
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
-
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
-
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
-
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
-
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Trading Information
- Previous Close Price
- $13.91
- Day Range
- $13.66–14.30
- 52-Week Range
- $2.75–15.02
- Bid/Ask
- $13.70 / $13.78
- Shares Outstanding
- 324.05M
- Market Cap
- $4.45B
- Volume/Avg
- 4M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 62.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 562
- Website
- https://www.abcellera.com
Valuation
|
Metric
|
ABCL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.70 |
Price/Sales | 62.63 |
Price/Cash Flow | — |
Price/Earnings
ABCL
Financial Strength
|
Metric
|
ABCL
|
|---|---|
Quick Ratio | 11.95 |
Current Ratio | 12.77 |
Interest Coverage | — |
Quick Ratio
ABCL
Profitability
|
Metric
|
ABCL
|
|---|---|
Return on Assets (Normalized) | −9.06% |
Return on Equity (Normalized) | −12.77% |
Return on Invested Capital (Normalized) | −12.38% |
Return on Assets
ABCL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@H&rMM | LOCK|RRfh> | $128B | |||
| Moderna Inc
MRNA
| LOCK|$?Q<L! | LOCK|s& | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n$f%X@& | LOCK|kH%lQ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|$&>f!G& | LOCK|M& | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|bBV<Lk | LOCK|@W | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>kMT%yw | LOCK|%kBJ$ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|WT$$!n$ | LOCK|$^<C? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|F&@Rq## | LOCK|>& | $24B | |||
| Incyte Corp
INCY
| LOCK|>Bx%HcD | LOCK|Vw | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$SB>?k | LOCK|Z@ | $15B |
United States